A computational bioinformatics analysis of gene expression identifies candidate agents for prostate cancer

Andrologia. 2014 Aug;46(6):625-32. doi: 10.1111/and.12127. Epub 2013 Jun 24.

Abstract

Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males worldwide. Although great progress has been made, the molecular mechanisms of prostate cancer are far from being fully understood and treatment of this disease remains palliative. In this study, we sought to explore the molecular mechanism of prostate cancer and then identify biologically active small molecules capable of targeting prostate cancer using a computational bioinformatics analysis of gene expression. A total of 3068 genes, involved in cell communication, development, localisation and cell proliferation, were differentially expressed in prostate cancer samples compared with normal controls. Pathways associated with signal transduction, immune response and tumorigenesis were dysfunctional. Further, we identified a group of small molecules capable of reversing prostate cancer. These candidate agents may provide the groundwork for a combination therapy approach for prostate cancer. However, further evaluation for their potential use in the treatment of prostate cancer is still needed.

Keywords: Gene ontology; pathway; prostate cancer; small molecules.

MeSH terms

  • Case-Control Studies
  • Computational Biology
  • Drug Discovery
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Ontology
  • Heterogeneous-Nuclear Ribonucleoproteins / genetics
  • Humans
  • Male
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / etiology
  • Prostatic Neoplasms / genetics*
  • Signal Transduction / drug effects
  • Signal Transduction / genetics

Substances

  • Heterogeneous-Nuclear Ribonucleoproteins